IBDEI1D8 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24193,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,24194,0)
 ;;=586.^^133^1473^5
 ;;^UTILITY(U,$J,358.3,24194,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24194,1,1,0)
 ;;=1^586.
 ;;^UTILITY(U,$J,358.3,24194,1,2,0)
 ;;=2^RENAL FAILURE NEC
 ;;^UTILITY(U,$J,358.3,24194,2)
 ;;=^104733
 ;;^UTILITY(U,$J,358.3,24195,0)
 ;;=694.9^^133^1474^1
 ;;^UTILITY(U,$J,358.3,24195,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24195,1,1,0)
 ;;=1^694.9
 ;;^UTILITY(U,$J,358.3,24195,1,2,0)
 ;;=2^BULLOUS DERMATOSES NOS
 ;;^UTILITY(U,$J,358.3,24195,2)
 ;;=^187900
 ;;^UTILITY(U,$J,358.3,24196,0)
 ;;=695.10^^133^1474^2
 ;;^UTILITY(U,$J,358.3,24196,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24196,1,1,0)
 ;;=1^695.10
 ;;^UTILITY(U,$J,358.3,24196,1,2,0)
 ;;=2^ERYTHEMA MULTIFORME NOS
 ;;^UTILITY(U,$J,358.3,24196,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,24197,0)
 ;;=696.1^^133^1474^4
 ;;^UTILITY(U,$J,358.3,24197,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24197,1,1,0)
 ;;=1^696.1
 ;;^UTILITY(U,$J,358.3,24197,1,2,0)
 ;;=2^PSORIASIS
 ;;^UTILITY(U,$J,358.3,24197,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,24198,0)
 ;;=695.81^^133^1474^5
 ;;^UTILITY(U,$J,358.3,24198,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24198,1,1,0)
 ;;=1^695.81
 ;;^UTILITY(U,$J,358.3,24198,1,2,0)
 ;;=2^STAPHLYCOCCAL SCALED SKIN SYND
 ;;^UTILITY(U,$J,358.3,24198,2)
 ;;=^113858
 ;;^UTILITY(U,$J,358.3,24199,0)
 ;;=695.13^^133^1474^6
 ;;^UTILITY(U,$J,358.3,24199,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24199,1,1,0)
 ;;=1^695.13
 ;;^UTILITY(U,$J,358.3,24199,1,2,0)
 ;;=2^STEVENS-JOHNSON SYNDROME
 ;;^UTILITY(U,$J,358.3,24199,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,24200,0)
 ;;=695.15^^133^1474^7
 ;;^UTILITY(U,$J,358.3,24200,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24200,1,1,0)
 ;;=1^695.15
 ;;^UTILITY(U,$J,358.3,24200,1,2,0)
 ;;=2^TOXIC EPIDRML NECROLYSIS
 ;;^UTILITY(U,$J,358.3,24200,2)
 ;;=^336638
 ;;^UTILITY(U,$J,358.3,24201,0)
 ;;=695.9^^133^1474^3
 ;;^UTILITY(U,$J,358.3,24201,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24201,1,1,0)
 ;;=1^695.9
 ;;^UTILITY(U,$J,358.3,24201,1,2,0)
 ;;=2^ERYTHEMATOUS SKIN COND NEC
 ;;^UTILITY(U,$J,358.3,24201,2)
 ;;=^123902
 ;;^UTILITY(U,$J,358.3,24202,0)
 ;;=441.9^^133^1475^2
 ;;^UTILITY(U,$J,358.3,24202,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24202,1,1,0)
 ;;=1^441.9
 ;;^UTILITY(U,$J,358.3,24202,1,2,0)
 ;;=2^ANEURYSM,AORTIC W/O RUPTURE,SITE UNSPEC
 ;;^UTILITY(U,$J,358.3,24202,2)
 ;;=^9277
 ;;^UTILITY(U,$J,358.3,24203,0)
 ;;=442.9^^133^1475^3
 ;;^UTILITY(U,$J,358.3,24203,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24203,1,1,0)
 ;;=1^442.9
 ;;^UTILITY(U,$J,358.3,24203,1,2,0)
 ;;=2^ANEURYSM,NON-AORTIC,SITE UNSPEC
 ;;^UTILITY(U,$J,358.3,24203,2)
 ;;=^7390
 ;;^UTILITY(U,$J,358.3,24204,0)
 ;;=710.3^^133^1475^6
 ;;^UTILITY(U,$J,358.3,24204,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24204,1,1,0)
 ;;=1^710.3
 ;;^UTILITY(U,$J,358.3,24204,1,2,0)
 ;;=2^DERMATOMYOSITIS
 ;;^UTILITY(U,$J,358.3,24204,2)
 ;;=^33162
 ;;^UTILITY(U,$J,358.3,24205,0)
 ;;=446.5^^133^1475^7
 ;;^UTILITY(U,$J,358.3,24205,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24205,1,1,0)
 ;;=1^446.5
 ;;^UTILITY(U,$J,358.3,24205,1,2,0)
 ;;=2^GIANT CELL ARTERITIS
 ;;^UTILITY(U,$J,358.3,24205,2)
 ;;=^117658
 ;;^UTILITY(U,$J,358.3,24206,0)
 ;;=446.20^^133^1475^8
 ;;^UTILITY(U,$J,358.3,24206,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24206,1,1,0)
 ;;=1^446.20
 ;;^UTILITY(U,$J,358.3,24206,1,2,0)
 ;;=2^HYPERSENSITIVITY ANGIITIS, UNS
 ;;^UTILITY(U,$J,358.3,24206,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,24207,0)
 ;;=446.3^^133^1475^9
 ;;^UTILITY(U,$J,358.3,24207,1,0)
 ;;=^358.31IA^2^2
 ;;
 ;;$END ROU IBDEI1D8
